Select therapeutic use:
Indications for ZERIT:
≥60kg: 40mg every 12hrs; <60kg: 30mg every 12hrs. Renal impairment: ≥60kg (CrCl 26–50mL/min): 20mg every 12hrs; (CrCl 10–25mL/min): 20mg every 24hrs. <60kg (CrCl 26–50mL/min): 15mg every 12hrs; (CrCl 10–25mL/min): 15mg every 24hrs. Hemodialysis: ≥60kg: 20mg every 24hrs; <60kg: 15mg every 24hrs. Coincide dose for end of dialysis and give at same time of day on non-dialysis days.
≤13 days: 0.5mg/kg every 12hrs. ≥14 days: (<30kg): 1mg/kg every 12hrs. ≥30kg: as adult. Renal impairment: insufficient data.
Suspend if lactic acidosis or hepatotoxicity (eg, hepatomegaly and steatosis) occurs. Women, obesity, or prolonged nucleoside exposure: increased risk of toxicity. Pre-existing liver dysfunction, hepatitis, or other risk factors of liver disease; monitor. Increased risk of peripheral neuropathy in advanced HIV disease, history of peripheral neuropathy, or when concomitant neurotoxic drugs; monitor and consider permanent discontinuation if develops. Suspend if pancreatitis is suspected; if confirmed may restart with caution and monitor closely. Monitor for signs/symptoms of lipoatrophy. Renal impairment. Diabetes (oral soln). Elderly. Pregnancy (Cat.C): monitor for lactic acidosis if used with didanosine. Nursing mothers: not recommended.
Avoid concomitant zidovudine. Increased risk of pancreatitis, hepatotoxicity, severe peripheral neuropathy with hydroxyurea; avoid. Caution with doxorubicin, ribavirin. Monitor for treatment-associated toxicities with interferon-alpha with or without ribavirin.
Nucleoside analogue (reverse transcriptase inhibitor).
Headache, diarrhea, nausea, vomiting, peripheral neurologic symptoms, rash, elevated liver enzymes, elevated amylase; pancreatitis, lactic acidosis or severe hepatomegaly with steatosis, lipoatrophy, immune reconstitution syndrome.
Register pregnant patients exposed to stavudine by calling (800) 258-4263.